Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Sponsor: Exosome Diagnostics, Inc.
Suspended
This trial was suspended. No reason was provided.
This observational or N/A phase trial investigates Metastatic Castrate Resistant Prostate Cancer and is currently suspended. Exosome Diagnostics, Inc. leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Suspended
-
Jul 2024 — Sep 2024 [monthly]
Suspended
-
Nov 2022 — Jul 2024 [monthly]
Suspended
Status: Active Not Recruiting → Suspended
-
Dec 2021 — Nov 2022 [monthly]
Active Not Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Mar 2019 — Nov 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Exosome Diagnostics, Inc.
- Yale University
For direct contact, visit the study record on ClinicalTrials.gov .